医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Medworxx Announces Entry into Australian Market with its Patient Flow Solution

2013年04月18日 PM01:55
このエントリーをはてなブックマークに追加


 

TORONTO

With strong traction in Canada and robust growth in the UK, Medworxx Solutions Inc. (“Medworxx”) (TSX VENTURE: MWX) today announced their expansion into Australia. Medworxx, along with its partner, EQhealth, have begun to actively market into the Australian base.

Due to the similarities between the Canadian, UK and Australian health systems, Medworxx expansion into Australia is a natural extension. With 82,800 hospital beds in Australia, there is significant opportunity for impact that provides for quantifiable increases in efficiency from implementing Medworxx Patient Flow solution.

“I am very excited to be working with the Medworxx team and their solution. There is great applicability in the Australian hospital market with access, patient flow, and readmission rates being high areas of focus,” said Anita Grindlay, Director, EQhealth. “The provision of real time utilisation data from the Medworxx solution will provide hospitals with the information needed to facilitate improvements in efficiency and effectiveness of care which is of benefit to hospitals, patients, and payers.”

Medworxx and EQhealth are performing patient flow diagnostic audits at Eastern Health and Cabrini Health in Australia. Similar audits in the UK have proven to be effective in identifying hospital patient flow barriers and delays. Two UK patient flow diagnostic audit sites – The Royal Liverpool and Broadgreen University Hospitals, and South Tees Hospitals NHS Foundation Trust – became users of the Medworxx Patient Flow solution. Furthermore, The Royal Liverpool and Broadgreen University Hospitals won the national 2012 EHI Awards’ category of ‘Outstanding work in IT-enabled change in healthcare’ for implementing Medworxx Clinical Criteria to enable and sustain greater patient flow within its busy hospitals.

“Australia, because of its health system similarities, represents a great opportunity for Medworxx. Early indications show that Medworxx meets a universal need to measure and monitor appropriate lengths of stay,” says Dan Matlow, CEO and President of Medworxx. “With 33% of the Canadian acute-care beds, and approximately 2,000 UK hospital beds, our technology and methodology is validated and proven to be effective, and we look forward to seeing its adoption in Australia.”

About Medworxx

Medworxx delivers health information solutions to over 350 hospitals internationally; including Canada, United States and United Kingdom. Medworxx helps hospitals meet patient flow challenges, and requirements in compliance and education. Medworxx Clinical Criteria – flagship of Medworxx Patient Flow that includes electronic bed board and independent assessment components – currently serves over 33% of the acute care beds in Canada. Founded in 2004, Medworxx is based in Toronto, ON, and publicly traded on the TSX Venture Exchange: MWX.

Visit: http://www.medworxx.com/

Disclaimer

The statements made in this press release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the company’s expectations and projections. The TSX Venture Exchange has not reviewed this press release and neither approved nor disapproved the information contained in this press release.

CONTACT

Media
Medworxx
Susan Gershman
T: 1.800.321.1591 |
T: 416.642.1278 x322
sgershman@medworxx.com
| www.medworxx.com
or
Dan
Matlow
President & Chief Executive Officer
T:
1.800.321.1591 | T: 416.642.1278 x311
dmatlow@medworxx.com
| www.medworxx.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent